Physician profile
Luis Hernandez
NPI 1619152113
$1,743.98
in general payments reported to CMS, 2019-2025
18 companies · $49.35 in 2025
The $49.35 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $75.43 · 2021: $218 · 2022: $87.81 · 2023: $456 · 2024: $244 · 2025: $49.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $510.62 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $294.43 | 2019-2023 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $196.52 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.64 | 2021-2024 | |
| Novo Nordisk INC | $97.18 | 2019-2023 | |
| Abbvie INC. | $75.23 | 2023 | |
| Janssen Pharmaceuticals, INC | $65.29 | 2019 | |
| Medtronic Vascular, INC. | $62.59 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.11 | 2024-2025 | Jardiance |
| Amarin Pharma, INC. | $37.67 | 2020-2021 | |
| Mylan Specialty L.P. | $25.73 | 2024 | Yupelri |
| Genentech USA, INC. | $23.43 | 2020 | |
| Exact Sciences Corporation | $22.97 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $21.20 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.33 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.23 | 2025 | Zoryve |
| Dexcom, INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.